Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659929 · ClinicalTrials.gov registry record · Phase 3
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
A Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Arbor Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT03659929: Completed Phase 3 study of Attention Deficit Hyperactivity Disorder, sponsored by Arbor Pharmaceuticals.
NCT03659929 is a Phase 3 study of Attention Deficit Hyperactivity Disorder that has completed, run by Arbor Pharmaceuticals. The registered enrollment target is 320 participants, above the 213-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03659929, a Phase 3 study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Arbor Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
Primary Outcome
Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Amphetamine Sulfate
Study Locations (20)
Florida
- 108: Meridien Research - Bradenton
- 103: Gulfcoast Clinical Research Center - Fort Myers
- 129: Sarkis Clinical Trials - Gainesville
- 105: Meridien Research - Lakeland
- 120: Meridien Research - Maitland
- 130: Medical Research Group of Central Florida - Orange City
- 123: APG Research, LLC - Orlando
- 115: Clinical Neuroscience Solutions (CNS), Inc. - Orlando
California
- 114: Pharmacology Research Institute - Encino
- 133: Collaborative Neuroscience Network - Garden Grove
- 124: Pharmacology Research Institute - Newport Beach
Michigan
- 134: Rochester Center for Behavioral Medicine - Rochester Hills
- 128: Clinical Neurophysiology Services - Sterling
New Jersey
- 116: Alliance - Hassman Research Institute - Berlin
- 127: Center for Emotional Fitness - Cherry Hill
Connecticut
- 121: CT Clinical Research Associates - Cromwell
Georgia
- 104: Northwest Behavioral Research Center - Marietta
Idaho
- 131: Advanced Clinical Research, Inc. - Meridian
Illinois
- 113: Capstone Clinical Research - Libertyville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 3 |
What the finished NCT03659929 record still lists
NCT03659929 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 213-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03659929 names 20 study sites across 9 states, led by Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT03659929 about?
NCT03659929 is a clinical study titled "Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate". The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
What is the current status of trial NCT03659929?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2018-09-18. Estimated completion is 2019-04-12.
What conditions does trial NCT03659929 study?
This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.
What interventions are being tested in trial NCT03659929?
The interventions under investigation include: Placebo (DRUG), Amphetamine Sulfate (DRUG).
Who is sponsoring clinical trial NCT03659929?
This trial is sponsored by Arbor Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03659929 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03659929's enrollment target sits among peer trials
320 15th of 102 higher than 88 of 102 other Attention Deficit Hyperactivity Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
ACTIVE NOT RECRUITING · Phase 3
-
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
COMPLETED · Phase 3
-
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI